# Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

> **NCT06054698** · PHASE2 · UNKNOWN · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Overweight or Obesity

## Interventions

- **DRUG:** HRS9531 injection
- **DRUG:** HRS9531 injection Placebo

## Key facts

- **NCT ID:** NCT06054698
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10
- **Primary completion:** 2024-08
- **Final completion:** 2024-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06054698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06054698, "Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06054698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*